VivoSeq
Other

Chronic Prostatitis

19

Pipeline Programs↗

3

Active Trials↗

15

Companies Involved↗

Chronic Prostatitis is an emerging landscape with 19 programs across 15 companies. The most active players are Aquinox Pharmaceuticals (Canada) Inc., Bristol-Myers Squibb, Bayer. 1 therapy is approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

6/100

Mech. Concentration

10/100

Completion Rate

82/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Aquinox Pharmaceuticals (Canada) Inc.

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 2Amgen logo

Amgen

1 program

Phase 2Astellas logo

Astellas

1 program

Phase 2AbbVie logo

AbbVie

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

22

clinical trials

Completed14 · 64%
Terminated3 · 14%
Unknown status2 · 9%
Recruiting2 · 9%
Not yet recruiting1 · 5%

Clinical Trials

Trial Activity

22 trials

The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Recruiting·AAJU Pharm Co., Ltd.·Phase 4·NCT06345014·332 enrolled
Risk Factors for Chronic Prostatitis Patients in Northwest China
Recruiting·SShaanxi Provincial People's Hospital·N/A·NCT06385977·400 enrolled
Extracorporeal Shock-Wave Therapy (ESWT) vs Phytotherapy vs Combined in Treatment of Chronic Prostatitis
Not yet recruiting·—·N/A·NCT07066735·90 enrolled
Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
Completed·WWatson Pharmaceuticals·Phase 2·NCT00740779·153 enrolled
The Effect of Cinnamon on Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome; a Pilot Study
Completed·—·Phase 1·NCT03946163·60 enrolled
Efficacy of Phycocyanin and Palmitoylethanolamide for the Treatment of Chronic Prostatitis Symptoms
Completed·CClinica Urologica Molinette - Città della Saliute e della Scienza·Phase 4·NCT07013890·48 enrolled
Non Interventional Study of Levofloxacin in Chronic Prostatitis
Completed·—·N/A·NCT02711943·500 enrolled
An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Completed·KKenneth Peters, MD·Phase 2·NCT00701311·21 enrolled
Efficiency and Safety of the Drug Ingaron (Interferon-gamma Human Recombinant) in the Treatment of Chronic Prostatitis
Completed·SSPP Pharmaclon Ltd.·Phase 3·NCT05378646·30 enrolled
Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00371033·324 enrolled
Chronic Prostatitis Collaborative Research Network Clinical Trial- Ciprofloxacin and Tamsulosin
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT04552431·196 enrolled
Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS)
Completed·UUniversity of Giessen·Phase 3·NCT00919893·139 enrolled
Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00103402·272 enrolled
An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logoJohnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00402688·242 enrolled
Efficacy and Safety of Ningmitai Capsule in Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Completed·XXintian Pharmaceutical·Phase 4·NCT05890235·323 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)